Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness

Abhishek Maiti • 2 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Abhishek Maiti, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II study comparing outcomes of older acute myeloid leukemia (AML) patients receiving DEC10-VEN vs. intense chemotherapy, overall and after stratification by ‘fitness’ for intense chemotherapy using a validated treatment-related mortality score. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abhishek Maiti

ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML
6:45
γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML
Abhishek Maiti • 10 Sep 2025
Rationale for 10-day decitabine with venetoclax for high-risk AML
2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
Venetoclax with decitabine for high-risk AML and MDS
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Abhishek Maiti • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Abhishek Maiti • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Abhishek Maiti • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Abhishek Maiti • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals